Privo Technologies Receives U.S. FDA Orphan Drug Designation ...Middle East

PR Newswire - News
Privo Technologies Receives U.S. FDA Orphan Drug Designation
PEABODY, Mass., Aug. 12, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo") announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Privo's PRV platform delivery of cisplatin for the treatment of carcinoma in situ (CIS) of the...

Hence then, the article about privo technologies receives u s fda orphan drug designation was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Privo Technologies Receives U.S. FDA Orphan Drug Designation )

Apple Storegoogle play

Last updated :

Also on site :



Latest News